Literature DB >> 31092063

Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity.

Nicholas T Bello1,2.   

Abstract

Entities:  

Keywords:  Bupropion; contrave; naltrexone; obesity; opioid resistant analgesia; psoriasis

Mesh：

Substances：

Year:  2019        PMID： 31092063     DOI： 10.1080/14740338.2019.1618268

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN： 1474-0338            Impact factor:   4.250


× No keyword cloud information.
  3 in total

1.  An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder.

Authors:  Elvira Anna Carbone; Mariarita Caroleo; Marianna Rania; Giuseppina Calabrò; Filippo Antonio Staltari; Renato de Filippis; Matteo Aloi; Francesca Condoleo; Franco Arturi; Cristina Segura-Garcia
Journal:  Eat Weight Disord       Date:  2020-04-30       Impact factor: 4.652

Review 2.  Cardiovascular Risks and Benefits of Medications Used for Weight Loss.

Authors:  Carolyn T Bramante; Sarah Raatz; Eric M Bomberg; Megan M Oberle; Justin R Ryder
Journal:  Front Endocrinol (Lausanne)       Date:  2020-01-15       Impact factor: 5.555

Review 3.  Plant-Based Diet as a Strategy for Weight Control.

Authors:  Stanislava Ivanova; Cédric Delattre; Diana Karcheva-Bahchevanska; Niko Benbasat; Vanya Nalbantova; Kalin Ivanov
Journal:  Foods       Date:  2021-12-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.